Comparison of sildenafil and estrogen for improvement of uterine health in patients with infertility
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: N972- Female infertility of uterine origin
- Registration Number
- CTRI/2022/02/040244
- Lead Sponsor
- SRM College Of Pharmacy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Primary and secondary infertility.
Endometrial lining thickness <7mm in pre-ovulatory phase of menstrual cycle.
Exclusion Criteria
Women with major health problems (i.e.cardiovascular disease,endocrine abnormalities,Renal and liver disease, patients with history of seizures .
Uterine structural anomalies and other pathologies such as endometrial polyps,severe intrauterine adhesion,hydrosalpinx or pyosalpinx.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the improvement in endometrial thickness between vaginal sildenafil and oral <br/ ><br>estradiol valerate in patients with infertility.Timepoint: Baseline ET,5days
- Secondary Outcome Measures
Name Time Method To compare the improvement of endometrial vascularity between vaginal sildenafil and <br/ ><br>oral estradiol valerate. <br/ ><br> <br/ ><br>To compare the pregnancy rate outcomes among patients treated with vaginal sildenafil and <br/ ><br>oral estradiol valerate.Timepoint: Baseline PI,5Days <br/ ><br> <br/ ><br>Baseline pregnancy rate ,4weeks